Lead Product(s): CAN106
Therapeutic Area: Hematology Product Name: CAN106
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: WuXi Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2021
CANbridge is developing CAN106 for the treatment of multiple diseases associated with complement dysregulation, including PNH. CAN106 comes out of the strategic partnership between CANbridge and WuXi Biologics in collaboration with Privus Biologics.